Singapore- Celgene and German biotech Evotec AG have inked a long-term strategic drug discovery and development partnership to identify new cancer therapies, 18 months after the two companies allied on neurodegeneration work.
Under the terms of collaboration, Evotec will receive $65M upfront, and may be eligible to receive significant milestone payments as well as tiered royalties on each licensed programme. Celgene receives exclusive opt-in rights to license worldwide rights to all programmes developed within this collaboration.
